The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL).

Read more here:
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients